

10/563310

IAP20 Rec'd 1707PTO 29 DEC 2005

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application : JÖRGEN CARLSSON, et al.
Serial No. :
Filed : HEREWITH
For : POLYPEPTIDES HAVING BINDING
AFFINITY FOR HER2
Examiner :
Attorney Docket : 102821-202
Group Art Unit :
Confirmation No. :
Customer No. : 27267

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450 on 29 DEC 2005.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully
requested to consider the references cited on attached Form PTO-
1449. A copy of each reference has been previously submitted
from the International Bureau. It is respectfully requested that
the information be expressly considered during the prosecution of
this application, and that the reference(s) be made of record
therein and appear among the "References Cited" on any patent to
issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed
within three months of the U. S. filing date OR before the
mailing date of a first Office Action on the merits. No
certification or fee is required.

- [] 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- [] Please charge Deposit Account No. 23-1665 in the amount of \$240.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$240.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- [] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
- [] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

10/563310

1AP29 Rec'd PCT/PTO 29 DEC 2005

Page 3 of 3

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

JÖRGEN CARLSSON, et al.

Date: 29 DEC 2005

By:

Todd E. Garabedian

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN and DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Facsimile: (203) 782-2889

10/563310

IAP20 Rec'd FCT/PTO 29 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application : JÖRGEN CARLSSON, et al.
Serial No. :
Filed : HEREWITH
For : POLYPEPTIDES HAVING BINDING
AFFINITY FOR HER2
Examiner :
Attorney Docket : 102821-202
Group Art Unit :
Confirmation No. :
Customer No. : 27267

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria,
VA 22313-1450 on 29 DEC 2005.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

INFORMATION DISCLOSURE LETTER

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned represents that the closest art of which he
is presently aware has been cited herein and understands that
this statement shall not be construed as a representation that
no better art exists or that a thorough patentability search has
been made.

The undersigned further represents that the filing of this
Information Disclosure Statement shall not be construed to be an
admission that the information cited in the Statement is, or is
considered to be, material to patentability as defined in 37
C.F.R. § 1.56(b).

1. International Patent Application No. WO 0208263, 31 January 2002, Got-A-Gene, AB.
2. International Patent Application No. WO 0063243, 26 October 2000, Pharmacia & Upjohn AB.
3. International Patent Application No. WO 0101748, 11 January 2001, Genentech, Inc.
4. International Patent Application No. WO 0023580, 27 April 2000, Affibody Technology Sweden AB.
5. Protein Engineering, Design & Selection, vol. 17, no. 5, M. Wikman, et al., "Selection and Characterization of HER2/neu-binding affibody ligands", pp. 455-462.
6. Nature Biotechnology, vol. 15, August 1997, Karin Nord, et al., "Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain", pp. 772-777.

Applicants submit that copies of the above-cited references were cited in the International Search Report of International Application No. PCT/SE2004/001049 and transmitted to the USPTO via the International Bureau.

IAP20 Rec'd PCT/PTO 29 DEC 2005


If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

JÖRGEN CARLSSON, et al.

Date: 29 DEC 2005

By:



Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN and DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Fax: (203) 782-2889

INFORMATION DISCLOSURE		ATTY. DOCKET NO. 102821-202		SERIAL NO. 10/563310		
		APPLICANT(S): JÖRGEN CARLSSON, et al.				
		FILING DATE: HEREWITH		GROUP ART:		CONF NO:
U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NO.	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPR.
FOREIGN PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NO.	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	0208263 A2	31 January 2002	WO			
	0063243 A1	26 October 2000	WO			
	0101748 A2	11 January 2001	WO			
	0023580 A1	27 April 2000	WO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
Protein Engineering, Design & Selection, vol. 17, no. 5, M. Wikman, et al., "Selection and Characterization of HER2/neu-binding affibody ligands", pp. 455-462.						
Nature Biotechnology, vol. 15, August 1997, Karin Nord, et al., "Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain", pp. 772-777.						
EXAMINER:				DATE CONSIDERED:		
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>						